Undifferentiated Pleomorphic Sarcoma after Pirfenidone Use: A Case Report | Zendy

Christine Moore | Zendy; Aaysha Kapila | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Undifferentiated Pleomorphic Sarcoma after Pirfenidone Use: A Case Report

Author(s) -

Christine Moore,

Aaysha Kapila

Publication year - 2018

Publication title -

the permanente journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.445

H-Index - 30

eISSN - 1552-5775

pISSN - 1552-5767

DOI - 10.7812/tpp/17-116

Subject(s) - pirfenidone , medicine , undifferentiated pleomorphic sarcoma , idiopathic pulmonary fibrosis , malignancy , sarcoma , pulmonary fibrosis , fibrosis , soft tissue sarcoma , lymph node , pathology , oncology , surgery , lung

Pirfenidone was approved in 2014 for the treatment of idiopathic pulmonary fibrosis. Pirfenidone inhibits several factors such as tissue growth factor-β and platelet-derived growth factor, leading to decreased epithelial and fibroblast proliferation and collagen synthesis. The drug improves progression-free survival and is well tolerated, with minimal side effects. However, data on its long-term effects are lacking.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research